Amarin

Amarin is a company focused on developing and commercializing therapies for patients with cardiovascular and cardiovascular risk conditions. Their primary area of development has been in lipid management, specifically targeting the treatment of dyslipidemia. The company is best known for its prescription drug Vascepa (icosapent ethyl), which is approved for certain patients with elevated triglyceride levels. Vascepa is an ultra-pure omega-3 fatty acid prescription medication. Amarin's research efforts have explored the potential benefits of icosapent ethyl in various cardiovascular risk reduction scenarios, including its efficacy in patients with established cardiovascular disease or multiple risk factors. The company operates globally, bringing its therapeutic solutions to patients in various markets. Amarin's approach involves rigorous scientific research and clinical trials to establish the safety and effectiveness of its products. Their mission centers on improving cardiovascular health outcomes for individuals at risk.